caa a22 4500 477071414 CHVBK 20180405111426.0 cr unu---uuuuu 170330e19960501xx s 000 0 eng 10.1007/BF01690096 doi (NATIONALLICENCE)springer-10.1007/BF01690096 Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice [Elektronische Daten] [F. Araujo, Y. Suzuki, J. Remington] The effectiveness of combinations of rifabutin with atovaquone, clindamycin, pyrimethamine, or sulfadiazine in the treatment of toxoplasmic encephalitis in a murine model was investigated. Doses of each drug that were not effective in reducing inflammation in the brain of mice with toxoplasmic encephalitis when used alone were used in combination with a dose of rifabutin which was minimally effective. At the end of each period of therapy (15 or 30 days), brains of mice were examined histopathologically and the severity of the inflammatory lesions scored. Treatment with rifabutin in combination with pyrimethamine or sulfadiazine did not reduce brain inflammation significantly when compared to treatment with each drug alone. In contrast, treatment with rifabutin plus atovaquone for 15 or 30 days or with rifabutin plus clindamycin for 15 days resulted in statistically significant reduction in the inflammation. These results suggest that combining rifabutin with certain drugs that are active againstToxoplasma gondii may be useful for the treatment of toxoplasmic encephalitis in humans and may allow for a reduction in dosage of either or both drugs with a resulting reduction in untoward side effects. Springer-Verlag, 1996 Araujo F. Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, 94301, Palo Alto, California, USA aut Suzuki Y. Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, 94301, Palo Alto, California, USA aut Remington J. Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, 94301, Palo Alto, California, USA aut European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/5(1996-05-01), 394-397 0934-9723 15:5<394 1996 15 10096 https://doi.org/10.1007/BF01690096 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01690096 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Araujo F. Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, 94301, Palo Alto, California, USA aut NATIONALLICENCE 700 1- Suzuki Y. Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, 94301, Palo Alto, California, USA aut NATIONALLICENCE 700 1- Remington J. Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, 94301, Palo Alto, California, USA aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/5(1996-05-01), 394-397 0934-9723 15:5<394 1996 15 10096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer